Wealthspring Capital’s Bellevue Life Sciences Acquisition Corp. Rights BLACR Stock Holding History

Wealthspring Capital’s Portfolio BLACR Stock Details BLACR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-11,900	Closed	-$1.36K	–	109
2024 Q4	$1.36K	Sell	11,900 -1,000	-8%	-$125	﹤0.01%	79
2024 Q3	$1.34K	Hold	12,900	–	–	﹤0.01%	70
2024 Q2	$1.3K	Sell	12,900 -3,550	-22%	-$485	﹤0.01%	57
2024 Q1	$2.24K	Sell	16,450 -6,100	-27%	-$932	﹤0.01%	54
2023 Q4	$3.04K	Buy	+22,550	New	+$3.64K	﹤0.01%	49

Wealthspring Capital's BLACR Position: Q1 2025 in Review

Wealthspring Capital sold out of Bellevue Life Sciences Acquisition Corp. Rights (BLACR) in Q1 2025, closing a stake of 11,900 shares — an estimated $1.36K sold.

Wealthspring Capital first reported a position in BLACR in Q4 2023 and held it in 5 quarters. The position peaked at $3.04K in Q4 2023. 0 funds tracked by Wall St. Rank hold BLACR as of Q1 2025.

Wealthspring Capital reported no remaining Bellevue Life Sciences Acquisition Corp. Rights position as of Q1 2025 after selling out during the quarter.
Wealthspring Capital sold 11,900 Bellevue Life Sciences Acquisition Corp. Rights shares in Q1 2025, an estimated $1.36K.
Wealthspring Capital first reported a position in Bellevue Life Sciences Acquisition Corp. Rights in Q4 2023 and held it in 5 quarters.
Wealthspring Capital's Bellevue Life Sciences Acquisition Corp. Rights position peaked at $3.04K in Q4 2023.
0 funds tracked by Wall St. Rank held Bellevue Life Sciences Acquisition Corp. Rights as of Q1 2025.

Based on Wealthspring Capital's 13F filing for Q1 2025, filed 2 May 2025.